Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.

MLA

Liu, Yang, et al. “Successful Use of Very Low Dose Subcutaneous Decitabine to Treat High-Risk Myelofibrosis with Sweet Syndrome That Was Refractory to 5-Azacitidine.” Leukemia & Lymphoma, vol. 55, no. 2, Feb. 2014, pp. 447–49. EBSCOhost, https://doi.org/10.3109/10428194.2013.802315.

APA

Liu, Y., Tabarroki, A., Billings, S., Visconte, V., Rogers, H. J., Hasrouni, E., Englehaupt, R., Kalaycio, M., Sekeres, M. A., Saunthararajah, Y., & Tiu, R. V. (2014). Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. Leukemia & Lymphoma, 55(2), 447–449. https://doi.org/10.3109/10428194.2013.802315

Chicago

Liu, Yang, Ali Tabarroki, Steven Billings, Valeria Visconte, Heesun J Rogers, Edy Hasrouni, Ricki Englehaupt, et al. 2014. “Successful Use of Very Low Dose Subcutaneous Decitabine to Treat High-Risk Myelofibrosis with Sweet Syndrome That Was Refractory to 5-Azacitidine.” Leukemia & Lymphoma 55 (2): 447–49. doi:10.3109/10428194.2013.802315.